Global Liver Institute Launches Final Nonalcoholic Steatohepatitis (NASH) Externally-Led Patient-Focused Drug Development Meeting Outcome Report (Washington, DC, Wednesday, March 9,...
Partnership Applications Now Open Washington, DC – March 7, 2022 – Global Liver Institute (GLI) will convene the fifth International NASH Day (#NASHday) on June 9, 2022 with the theme Stop NASH...
GLI’s Liver Action Network Supports World Obesity Day to Acknowledge Strong Connection Between NASH and Obesity As members of Global Liver Institute’s Liver Action Network (LAN), the undersigned...
(Washington, D.C., March 2, 2022) – Global Liver Institute (GLI) proudly announces the expansion of the Liver Action Network (LAN) to include a partnership with Empire Liver...
(Washington, DC, Wednesday, February 16, 2022)—Today, Global Liver Institute (GLI) applauds the confirmation of the new Food and Drug Administration (FDA) Commissioner Dr. Robert Califf. On Tuesday,...
Transforming the Public Consciousness with Conversations for and about the Rare Liver Disease Community WASHINGTON, DC, FEBRUARY 1, 2022 – Global Liver Institute (GLI), a patient-led...
POLICY PERSPECTIVE Rapid advancements to policy and committees welcomed in the new year. One of the most highlighted actions was the advancement of the nomination of Dr. Robert Califf as the...
Fatty liver disease (FLD) and nonalcoholic steatohepatitis (NASH) are increasing in prevalence worldwide, creating a major global public health crisis. To adequately educate patients, practitioners,...
As we enter a third calendar year marked by COVID-19, the Omicron variant has caused pandemic peaks in cases and hospitalizations. However, we also have a greater understanding of the disease–and...
Washington, DC, January 14, 2022 – In 2021, the Global Liver Institute (GLI) formed the Liver Action Network (LAN) to better synchronize engagement across the liver advocacy...
Recent News
Driving Progress in Rare Liver Disease Patient Story Feature: From Patient to Pioneer: Frans Frielink’s Journey with Alpha-1 MZ When years of fatigue, inflammation, and unanswered symptoms left him without a diagnosis, Frans Frielink, an engineer by...
From Patient to Pioneer: Frans Frielink’s Journey with Alpha-1 MZMy name is Frans Frielink, and I have over 40 years of experience in the semiconductor market in research and business. My background is deeply rooted in analytical thinking, problem-solving, and...
Smart Tools, Healthier Livers: How Digital Health Can Help You Take ControlWhether you know it or not, your liver plays a central role in your health. It has over 500 functions in the body, including filtering toxins from the blood and helping manage levels of sugar...
Budget Reconciliation Bill Passes with Steep Medicaid Cuts, Orphan Drug Exemption from Medicare Negotiation Congress passed H.R. 1 with the Vice President providing the tie-breaking vote in the Senate to pass the bill 51-50, the House passing the bill on July 3, and...
Advancing Screening, Science & AdvocacyA Note from the Director, Dr. Sharon H. Jaycox Reflections on the American Diabetes Association (ADA) Scientific Sessions I recently had the privilege of attending the ADA Scientific Sessions in Chicago. One of the key themes...
